Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Cancers
•
Endometrial Cancer
•
Medical Oncology
would you consider Pembrolizumab + Lenvatinib after progression on Carboplatin + Paclitaxel + Immunotherapy first line treatment of metastatic endometrial cancer
Related Questions
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?
Given the negative results of GOG-0238 but the positive results of the RUBY trial, how do you manage isolated vaginal cuff recurrence of endometrial cancer?
What is your preferred systemic regimen for MMR-proficient, high-grade endometrial cancer that recurs <1 year from adjuvant carboplatin/paclitaxel?
Will you be changing your management of locally advanced cervical cancer based on the results of the INTERLACE trial presented at ESMO 2023?
How do you treat a locally advanced cervix cancer in a patient who declines brachytherapy?
How would you palliate a large, symptomatic vaginal melanoma recurrence with limited small pelvic lymph node metastases?
